Financing Presents Obstacle for Clinical Development of Cytokinetics’ ALS Drug

San Francisco’s Cytokinetics is struggling to bring its ALS drug to market. After shedding its cancer program, the company has focused its activity on its ALS drug candidate, CK-2017357, now in its second phase II clinical trial. While the drug shows promise, it is not yet clear how the company will manage to finance the all-important Phase III efficacy trial.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail